TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25200552
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of vitamin D3 (250,000 IU) followed by oral maintenance vitamin D3/calcium (800 IU/500 mg)
Study: 22455355
Drug: Ethanol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.25 g/kg)
Study: 9800141
Drug: Ethanol and
Normalized name: Ethanol and glycine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol and Nitrous oxide (combination)
Study: 8777409
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of 10 mg moxisylyte
Study: 6107678
Drug: 13‐cis retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13‐cis retinoic acid (0.1 mg‐1.0 mg/kg body‐weight)
Study: 31304536
Drug: Ibrexafungerp 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrexafungerp 750 mg
Study: 31304536
Drug: Ibrexafungerp 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrexafungerp 500 mg
Study: 31304536
Drug: Micafungin (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (continued therapy)
Study: 27845219
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose tadalafil (5 mg)
Study: 25877748
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy after gefitinib
Study: 21219593
Drug: Cell phone-supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell phone-supported cognitive behavioural therapy (CBT) for anxiety disorders; specific dosage and duration not mentioned.
Study: 20875374
Drug: Tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol IR 100 mg
Study: 19203298
Drug: Oxycodone HCl
Normalized name: oxycodone HCl
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone HCl IR 15 mg
Study: 17893579
Drug: Lighter general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lighter general anesthesia (propofol 2 mug/mL and rimifentanil 2 ng/mL)
Study: 17893579
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (propofol 4 microg/mL and rimifentanil 4 ng/mL)
Study: 15321210
Drug: Bupivacaine 9.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 9.375 mg (15 ml of 0.0625%) with fentanyl 37.5 microg and adrenaline 37.5 microg
Study: 15321210
Drug: Bupivacaine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 15 mg (15 ml of 0.1%) with fentanyl 30 microg and adrenaline 30 microg
Study: 15321210
Drug: Bupivacaine 10
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 10 mg (4 ml of 0.25% ‐ test) followed by bupivacaine 20 mg (8 ml of 0.25% ‐ loading)
Study: 29266092
Drug: FEDWASH (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEDWASH (30 g CHO·h during SS + WASH during TT)
Study: 29266092
Drug: FEDPLA (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEDPLA (30 g CHO·h during SS + placebo wash during TT)
Study: 28419170
Drug: Couple-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple-based cognitive behaviour therapy (CBT)
Study: 28419170
Drug: One-to-one cognitive
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-to-one cognitive behaviour therapy (CBT)
Study: 23974823
Drug: Concomitant TMZ
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concomitant TMZ (75 mg/m²/day) during the first and last weeks of RT in the RT-TMZ-10.00 study
Study: 23974823
Drug: Concomitant TMZ
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concomitant TMZ (75 mg/m²/day) during all weeks of RT in the RT-TMZ-01.04 trial
Study: 23974823
Drug: Adjuvant TMZ
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant TMZ (200 mg/m²) administered for 5 days every 28 days
Study: 15990745
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate (CrPic) 1000 microg daily for 3 months
Study: 8720373
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1.8 g of n-3 PUFA)
Study: 2036564
Drug: Diluted media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted media (150 mgI/ml)
Study: 7055525
Drug: Extradural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural morphine (4mg before skin incision and an additional 4mg at skin closure)
Study: 28533226
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with concurrent trastuzumab (Arm C)
Study: 28533226
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with sequential trastuzumab (Arm B)
Study: 25643353
Drug: Low-iodine group
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-iodine group (270 mg I/mL, 100 kVp) with iterative reconstruction (IR)
Study: 25643353
Drug: High-iodine group
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-iodine group (370 mg I/mL, 120 kVp)
Study: 22987136
Drug: Amiodarone (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (group A; 219 patients) - intravenous infusion (15 mg/kg for 48 h postoperatively) after a loading dose (5 mg/kg)
Study: 22987136
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (group M; 219 patients) - loading dose (80 mg/kg over 30 min preoperatively) and then intravenous infusion (8 mg/kg/h for 48 h)
Study: 17523328
Drug: Synbiotic 2000
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic 2000 (lactobacilli preparations with 10^10 CFU and prebiotics)
Study: 11495873
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg po
Study: 11495873
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg po
Study: 9706735
Drug: Topiramate (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (doses not specified)
Study: 9706735
Drug: Topiramate (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (high doses)
Study: 9706735
Drug: Topiramate (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (doses beyond 600 mg/day)
Study: 7817799
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride treatment (60 mg NaF/day for 1-2 years)
Study: 7817799
Drug: Osteoporotic bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoporotic bone before fluoride treatment
Study: 24364538
Drug: Intranasal users
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal users
Study: 17333787
Drug: Prednisolone, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone, 30 mg/day for 10 days
Study: 17333787
Drug: Anti-tuberculosis (TB)
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tuberculosis (TB) drugs for 6 months
Study: 10929163
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate lozenges (12.8 mg)
Study: 1396796
Drug: Omnipaque (iohexol)
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omnipaque (iohexol) 350 mgI/ml
Study: 1396796
Drug: Telebrix (sodium-meglumine-ioxithalamate)
Normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telebrix (sodium-meglumine-ioxithalamate) 350 mgI/ml
Study: 2861365
Drug: Biodegradable polylactide‐glycolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biodegradable polylactide‐glycolide copolymer implants
Study: 2861365
Drug: Conventional metallic
Normalized name: Aluminum metal
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional metallic implants
Study: 28820746
Drug: D-Cycloserine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Cycloserine (125 mg) administered pre-exposure therapy
Study: 28820746
Drug: D-Cycloserine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Cycloserine (125 mg) administered post-exposure therapy
Study: 25403903
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg subcutaneously every 6 months for 3 years
Study: 25403903
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg subcutaneously every 6 months for 1 year (cross-over group)
Study: 24771706
Drug: Wrist self-monitoring
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wrist self-monitoring device with daily BP measurement for 24 weeks
Study: 14769778
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg 5‐MTHF
Study: 14747389
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folic acid
Study: 12365087
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment (ACE inhibitor, beta‐blocking drug or ARB)
Study: 12365087
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment (calcium channel‐blocking drug or thiazide diuretic)
Study: 12365087
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination therapy (one drug from group 1 and one drug from group 2)
Study: 12365087
Drug: Initial monotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial monotherapy maintained alone or in combination
Study: 9677171
Drug: STD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: STD treatment (directly observed, single oral dose)
Study: 9677171
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm received anthelminthic and iron-folate (directly observed, single oral dose)
Study: 2688238
Drug: Porcine insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine insulin (PI)
Study: 31870314
Drug: Multicomponent exercise
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent exercise intervention (twice a week for 16 weeks, 45-60 minutes each session)
Study: 19690548
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg m(‐2) over 30 min on days 1, 8, and 15, every 4 weeks for 3 cycles)
Study: 16803844
Drug: S-1 alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 alone (2 weeks of treatment and 1 week of rest for 6 months, followed by 2 weeks of treatment and 2 weeks of rest for 6 months)
Study: 16803844
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus PSK (the same regimen of S-1 plus daily PSK for 12 months)
Study: 12717216
Drug: Sirolimus plus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus plus steroids (SRL+ST)
Study: 12717216
Drug: Sirolimus with
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus with cyclosporine A plus steroids (SRL+CsA+ST)
Study: 9283538
Drug: Conscious sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conscious sedation with combined intravenous midazolam, morphine, and promethazine, plus deep sedation with etomidate
Study: 9283538
Drug: Propofol anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anesthesia administered by an attending anesthesiologist
Study: 27131407
Drug: Amaranth extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amaranth extract (2 g as single dose)
Study: 21142821
Drug: Tablets with
Normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets with resinate (dextromethorphan loaded into Amberlite IRP-69 resin)
Study: 21142821
Drug: Tablets with
Normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets with physical mixture (dextromethorphan physically mixed with resin)
Study: 21142821
Drug: Tablets with
Normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets with resinate
Study: 21142821
Drug: Tablets with
Normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets with physical mixture
Study: 21142821
Drug: Both tablets
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both tablets (resinate and physical mixture)
Study: 12856119
Drug: Intravenous teicoplanin
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous teicoplanin (6 mg/kg per 12 h for 48 h, then 6 mg/kg daily)
Study: 12856119
Drug: Subcutaneous teicoplanin
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous teicoplanin (30-min administration)
Study: 12856119
Drug: Subcutaneous teicoplanin
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous teicoplanin
Study: 1835223
Drug: Intravenous teicoplanin
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous teicoplanin
Study: 1780722
Drug: Gallium arsenide
Normalized name: GALLIUM ARSENIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallium arsenide laser treatment with standard conservative treatment
Study: 1780722
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser treatment with standard conservative treatment
Study: 28776304
Drug: Education about
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education about oral mucositis prevention, including training and Patient Education Booklet
Study: 28776304
Drug: Education about
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education about oral mucositis prevention
Study: 28027413
Drug: Omega 3
Normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omega 3 (1 gm three times daily for 3 months)
Study: 28027413
Drug: Dexamethasone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1.5 ml) and hyaluronidase (1500 IU) mixed with lignocaine (biweekly for 6 weeks) and placebo (for 3 months)
Study: 26482279
Drug: Lenvatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib plus everolimus (18 mg/day and 5 mg/day)
Study: 26482279
Drug: Single-agent lenvatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent lenvatinib (24 mg/day)
Study: 26482279
Drug: Single-agent everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-agent everolimus (10 mg/day)
Study: 22827783
Drug: Methimazole (MMI)
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (MMI) treatment
Study: 22827783
Drug: Radioiodine (RAI)
Normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine (RAI) treatment with thyroxine
Study: 17700991
Drug: Clazosentan 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazosentan 0.2 mg/kg/h
Study: 10599904
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg doxycycline daily for 14 days
Study: 1785703
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 0.5 M sodium citrate
Study: 29653858
Drug: rhNGF 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhNGF 10 μg/ml
Study: 29653858
Drug: rhNGF 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhNGF 20 μg/ml
Study: 12032038
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (EM; 17 mL of 2% lidocaine plus 2 mg of morphine)
Study: 12032038
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine (IVM; 17 mL of 2% lidocaine plus 0.2 mL of normal saline, followed by IVM 2 mg IV)
Study: 12032038
Drug: Control (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (17 mL of 2% lidocaine plus 0.2 mL of normal saline, followed by 0.2 mL of normal saline IV)
Study: 8561380
Drug: Psychotherapy (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy (long-term treatment)
Study: 8561380
Drug: Limited therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited therapy or choice of therapist due to insurance or managed care
Study: 31739848
Drug: Technology assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technology assisted sleep extension intervention (wearable sleep tracker, smartphone application, weekly didactic lessons, brief telephone coaching)
Study: 29851204
Drug: Vesatolimod (1-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vesatolimod (1-, 2-, or 4-mg) once weekly for 12 weeks
Study: 31874050
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once weekly for 12 weeks
Study: 29851204
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (300-mg daily) for 48 weeks
Study: 29231362
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy group (scraping therapy + xuanfei zhisou decoction)
Study: 29231362
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine group (xuanfei zhisou decoction)
Study: 25042213
Drug: QUIT intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: QUIT intervention of brief clinician advice and up to two drug-use health telephone sessions
Study: 17597256
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (0.1 mg/kg, maximum 5 mg)
Study: 11720695
Drug: Nortriptyline or
Normalized name: nortriptyline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline or Paroxetine (12 weeks treatment)
Study: 9497787
Drug: NG-monomethyl-L-arginine, 1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG-monomethyl-L-arginine, 1-4 mumol/min
Study: 21444270
Drug: Mouthrinse and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthrinse and antiseptic (as chlorhexidine agents)
Study: 7100223
Drug: (-)eburnamonine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)eburnamonine (100 mg infusion)
Study: 7100223
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with (-)eburnamonine (oral route)
Study: 20015193
Drug: Combined Parent
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Parent Training and Child Treatment (PT+CT)
Study: 18061705
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 400 mcg every 3 h
Study: 18061705
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline and d-cloprostenol 2.5 mg/h
Study: 11401178
Drug: Intravenous cilomilast
Normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cilomilast 1, 2, and 4 mg
Study: 11401178
Drug: Oral cilomilast
Normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cilomilast 15 mg
Study: 11401178
Drug: Oral cilomilast
Normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cilomilast 15 mg in fed subjects
Study: 11401178
Drug: Oral cilomilast
Normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cilomilast 15 mg in fasted subjects
Study: 11401178
Drug: Oral cilomilast
Normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cilomilast 15 mg with different dosing times
Study: 11401178
Drug: Oral cilomilast
Normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cilomilast 15 mg with aluminum hydroxide‐magnesium hydroxide
Study: 9566385
Drug: Estrogen-replacement therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-replacement therapy
Study: 3190163
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of vitamin C (200 mg/day)
Study: 3190163
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of vitamin C (2,000 mg/day)
Study: 26777745
Drug: Microbial cell
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbial cell preparation (treatment)
Study: 23842100
Drug: Intravitreal FCFD4514S
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal FCFD4514S (maximum tolerated dose: 10 mg)
Study: 15639065
Drug: Cerazette (75-microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerazette (75-microg desogestrel-only contraceptive pill) taken for 56 days with three tablets taken 12 hours late
Study: 10793299
Drug: A cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: A cocktail of daily doses of 6 g of aged garlic extract, 4-6 g of vitamin C, and 800 to 1200 IU of vitamin E